Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep881 | Late Breaking | ECE2021

Follicular thyroid carcinoma in a developing country : A retrospective study of 10 years

Aziz Abdul , Qamar Masood Muhammad , Sattar Saadia , Fatima Saira , Islam Najmul

IntroductionThe most common endocrine tumor is thyroid cancer. Follicular Thyroid Carcinoma (FTC) accounts for 5%–10% of all thyroid cancers. Patients with FTC frequently present with more advanced stage diseases and a higher occurrence of distant metastases because of the propensity of vascular invasion. FTC are mainly treated with surgery while radioactive iodine therapy (RAI) is main adjuvant therapy as per ATA guidelines. In many developing coun...

ea0032p284 | Clinical case reports - Thyroid / Others | ECE2013

Autoimmune hypothyroidism converted to hyperthyroidism: is it a common phenomenon?

Furqan Saira , Islam Najmul

Introduction: Graves’ disease and Hashimoto’s thyroiditis are the two autoimmune spectrum of thyroid disease. Cases of conversion from hyperthyroidism to hypothyroidism have been reported but conversion from hypothyroidism to hyperthyroidism is very rare although reported. We report a case of hypothyroidism that converted to a hyperthyroid state needing treatment.Case report: A 36 years old female presented with a 3 months history of easy fatig...

ea0094p60 | Metabolism, Obesity and Diabetes | SFEBES2023

Predictors of weight loss in a secondary care tier 3 specialist weight management service

Adapa Shashank , Hameed Saira , Izzi-Engbeaya Chioma

Background: A four-tiered system is currently in place for weight management in the National Health Service (NHS). Tier 3 comprises specialist weight management services and aims for a clinically meaningful weight loss of ≥5%, as recommended by the National Institute for Health and Care Excellence (NICE). Within the Imperial Weight Centre (IWC), patients receive support from a multi-disciplinary team including endocrinologists, surgeons, dietitians, nurs...

ea0094p141 | Thyroid | SFEBES2023

A rare but important side effect of anti-thyroid medication: Propylthiouracil-induced vasculitis

Fahad Khalid , Yousaf Saira , Pan Shwe

Background: We present a 47-year-old female, who is known to have recurrent Graves’ disease, developed vasculitic skin lesions upon treatment with propylthiouracil (PTU).Case details: She was diagnosed with Graves’ disease in 2020 and was started on propylthiouracil as she could not tolerate carbimazole. Propylthiouracil was stopped after 18 months. Her thyrotoxicosis recurred after 6 months. Two months after p...

ea0094p392 | Thyroid | SFEBES2023

A rare but important side effect of anti-thyroid medication: propylthiouracil-induced vasculitis

Fahad Khalid , Yousaf Saira , Pan Shwe

Background: We present a 47-year-old female, who is known to have recurrent Graves’ disease, developed vasculitic skin lesions upon treatment with propylthiouracil (PTU).Case details: She was diagnosed with Graves’ disease in 2020 and was started on propylthiouracil as she could not tolerate carbimazole. Propylthiouracil was stopped after 18 months. Her thyrotoxicosis recurred after 6 months. Two months after p...

ea0077p166 | Bone and Calcium | SFEBES2021

Systematic review of cardiovascular morbidity and mortality associated with primary hyperparathyroidism; does early surgical intervention improve the outcome?

Azad Fatima

Introduction: Primary hyperparathyroidism is associated with numerous cardiovascular complications including hypertension, left ventricular hypertrophy and calcification of cardiac valves. However NICE have not included cardiovascular complications as an indication of parathyroidectomy. This literature review will be focused on benefits of parathyroidectomy on cardiovascular complications of primary hyperparathyroidism.Methodology: Literature search done...

ea0086p105 | Neuroendocrinology and Pituitary | SFEBES2022

Case Series: Primary / neo-adjuvant 131I-MIBG therapy as a safe and effect treatment in the management of pheochromocytoma / paraganglioma

Onyema Michael , Crane James , Reynolds Saira , Whitelaw Benjamin

Background: As per 2014 Endocrine Society guidelines, 131I-MIBG therapy is usually reserved for metastatic or unresectable disease in patients with pheochromocytoma / paraganglioma. In this series, we describe three patients effectively treated with primary 131I-MIBG therapy. The indications were primary neo-adjuvant therapy prior to surgery, or palliative.Case series: Case 1 – 18-year-old male with a 60 mm para-aortic paragang...

ea0094op7.4 | RET and Endocrine Cancer | SFEBES2023

Primary ovarian failure after 131I-metaiodobenzylguanide (MIBG) therapy

Dhar Mili , Crane James , Heraghty Neil , Reynolds Saira

131I-metaiodobenzylguanide (MIBG) therapy, initially introduced in the 1980s, has emerged as a first-line to treatment of malignant phaeochromocytomas. Its other notable use has been in treating neuroblastomas occurring in childhood serving as an adjuvant prior to surgery or chemotherapy. An observed known late consequence of MIBG therapy is Primary ovarian failure (POI), characterised by menstrual irregularities over a period of 4 months associated with high Follicular stimul...

ea0099p83 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Expression of pro-inflammatory cytokines and fibrinogen in human diabetic nephropathy

Maqsood Maha , Sharif Saima , Rafaqat Saira , Naz Peter Shagufta

Background: Diabetic nephropathy (DN) is a micro-chronic diabetic complication brought on by changes in metabolism and hemodynamics. Inflammatory cytokines, generally IL-1β, IL-6 and IL-18 are linked in the development and advancement of DN. They act as pleiotropic polypeptides regulating inflammatory and immune responses through actions on cells. Fibrinogen is the liver-synthesized protein, with different functions and responses to both acute and chronic stimuli.AimThe a...